NEW YORK, Oct. 3 - Quark Biotech said Wednesday that it would use its gene and protein function profiling technology to supply AstraZeneca with potential cancer targets.

Under the terms of the deal, Quark, a Cleveland-based company that conducts most of its research in Israel, will provide AstraZeneca of London with 100 genes and proteins it identifies using its platform, known as BiFAR. The companies will also work together to evaluate and validate the function of these potential targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.